CARPENTIER-EDWARDS Pericardial Aortic Bioprosthesis

However, no study to date has evaluated specifically this complication in a ViV population. Thus, the present study aimed to evaluate baseline characteristics, management, and clinical outcomes of coronary obstruction as a complication of TAVI in patients with previous surgical aortic bioprosthesis through a systematic review.

CARPENTIER-EDWARDS Pericardial Aortic Bioprosthesis

 CARPENTIER-EDWARDS  Pericardial Aortic Bioprosthesis

Medtronic Bioprostheses for Replacement of Aortic …

– (A) Coronary protection with guide wire to facilitate access and stent placement in case of coronary obstruction after aortic valve transcatheter implantation for the treatment of bioprosthesis dysfunction. (B) Interaction between the guide wire and the transcatheter heart valve.

Edwards aortic pericardial bioprosthesis.

This study described the initial experience of a multidisciplinary group with transcatheter VIV implantation for the treatment of surgical bioprosthesis dysfunction in aortic position in high-risk surgical patients. Data were obtained in a clinical practice setting and confirmed their technical feasibility, providing the treated individuals with clinical and hemodynamic benefits in the first 30 days, which were maintained at the end of 1 year.

Using a Perceval Sutureless Aortic Bioprosthesis

Warfarin for Six Months for Bioprosthetic Aortic Valves

The main parameter considered for the choice of transcatheter aortic prosthesis to be implanted was the internal diameter of the previous surgical bioprosthesis, obtained from the manufacturer or as reported by the VIV Aortic application, developed by Bapat and UBQO Ltd. (London, United Kingdom). Echocardiography was used to assess the mechanism and consequences of prosthetic dysfunction, defining the integrity and mobility of the leaflets, left ventricular function, and the presence of pulmonary hypertension and associated valve diseases. In cases of dysfunction due to prosthesis regurgitation, the transesophageal echocardiography excluded the presence of paravalvular reflux. The CT-angiography of the aorta was the method used to determine the best approach. In case of non-availability of previous surgical data, the CT-angiography helped to analyze the surgical prosthesis diameters and to choose the most appropriate transcatheter prosthesis for VIV procedure. Coronary angiography was used for the assessment of associated coronary artery disease and to estimate the risk of coronary occlusion during valve implantation.

Aortic Valve Replacement With Perceval Bioprosthesis: Single-Center Experience With 617 Implants

Stentless Bioprostheses for Aortic Valve Replacement in …

The mechanism associated with coronary obstruction after TAVI-ViV has been the displacement of the bioprosthesis leaflet towards the coronary ostium in all patients; no cases of coronary obstruction related to the metal frame of transcatheter valves, nor to their leaflets, have been reported. Furthermore, according to the TAVI-ViV Global Registry, the coronary obstruction following TAVI-ViV was more frequent in supported bioprosthesis leaflets and in externally mounted leaflets (especially the Mitroflow® prosthesis) and also with supportless bioprostheses. In the case of the Mitroflow® prosthesis, the relatively long (~13mm) leaflets externally mounted on the supports (with stent), rather than internally as in most other supported prostheses, may be associated with a higher rate of coronary obstruction. In addition, the supportless bioprostheses (stentless) may also be associated with an increased risk of this complication. These bioprostheses are generally implanted in a supra-annular position, resulting in a shortening of the position of the coronary ostia in relation to the valve leaflets, which, together with the rodless stents, may facilitate an interaction of the prosthesis with the aortic wall and the coronary ostium ().

The Mosaic bioprosthesis in the aortic position: Hemodynamic performance after 2 years

3f Enable Aortic Bioprosthesis (model 6000) | …

A total of four publications describing seven patients were identified. Most patients (71%) were women, with mean age of 82±5 years, and STS-PROM score of 9.4±2.6%. Mean left coronary artery (LCA) ostium height and aortic root width were 8.8±1.5mm and 28.0±5.0mm, respectively. Most patients had stented bioprosthetic valves with externally mounted leaflets or stentless aortic bioprosthesis, and the LCA was involved in all patients. Percutaneous coronary intervention (PCI) was attempted in all patients and was successful in four (57%). In-hospital mortality was 42.9% (three cases), all of them after failed PCI.

Aortic Valve Replacement Using a Perceval Sutureless Aortic Bioprosthesis

The Trifecta aortic bioprosthesis (St

However, in a large multicenter registry recently published on coronary obstruction, with over 6,500 patients, the incidence in native aortic valves was 0.66%, much lower than the 2.48% of the patients submitted to previous surgical prostheses. This incidence is similar to that reported of 3.5%, described in a recent registry conducted worldwide considering only TAVI-ViV (Valve-in-Valve Global Registry), including 202 patients, and corroborates the presence of previous surgical bioprosthesis as a potential risk factor for this complication. The rates of coronary obstruction in recent studies evaluating this complication, both in native aortic valves and in surgical bioprostheses, are summarized in .